论文部分内容阅读
目的 在裸鼠肝脏建立人肝癌组织多药耐药(MDR)模型。方法 用组织学完整的原发性多药耐药人肝癌组织种植于裸鼠肝脏。然后分别用免疫组织化学方法(SP法)和逆转录 聚合酶链反应(RT PCR)法检测瘤源及裸鼠种植瘤组织中MDR1、LRP蛋白及其mRNA的表达。结果 裸鼠原位种植瘤保持了人肝癌组织MDR特性。瘤源MDR1、LRP蛋白表达分别为3 1.2 6%和2 7.18% ;其mRNA量分别为61.47%和5 6.71%。裸鼠种植瘤MDR1、LRP蛋白表达分别为(2 9.2 0±2 .81) %和(2 5 .44±2 .43 ) % ;其mRNA量分别为(65 .42±13 .5 9) %和(5 8.63±9.3 7) % ,两种组织中MDR1、LRP蛋白及其mRNA表达量差异无统计学意义(P >0 .0 5 )。结论 人肝癌组织裸鼠原位种植瘤可保持瘤源的MDR生物学特征,是体内研究人肝细胞癌MDR、筛选敏感化疗药物的较理想模型
Objective To establish a multidrug resistance (MDR) model of human hepatoma in nude mice. Methods The histologically intact primary multidrug-resistant human hepatocellular carcinoma was implanted in the liver of nude mice. Then the expression of MDR1 and LRP protein and their mRNA in tumor-bearing tumor and nude mice were detected by immunohistochemistry (SP method) and reverse transcription-polymerase chain reaction (RT PCR) respectively. Results Nude mice in situ implantation maintained the MDR characteristics of human hepatocellular carcinoma. The expressions of MDR1 and LRP were 32.6% and 21.78% respectively, and the mRNA levels of them were 61.47% and 5 6.71% respectively. The expression of MDR1 and LRP protein in nude mice implanted tumors were (2 9.2 0 ± 2.81)% and (25.44 ± 2.43)%, respectively. The mRNA expression of MDR1 and LRP in nude mice was (65.42 ± 13.59)% And (5 8.63 ± 9.37)%, respectively. There was no significant difference in the expression of MDR1 and LRP protein between the two tissues (P> 0.05). Conclusion In situ implantation of human hepatocellular carcinoma in nude mice can maintain the biological characteristics of MDR and is an ideal model for studying MDR in human hepatocellular carcinoma and screening sensitive chemotherapeutic drugs in vivo